AstraZeneca Aims for $20 Billion in Revenue by 2030
Pharma group believes successful medicines from its clinical trials could generate $20bn in revenue by 2030.
AstraZeneca, once viewed as an underdog, is now poised to solidify its status as a leading pharmaceutical giant. With a market capitalization nearing £200 billion, the company has set an ambitious goal: nearly doubling its revenues to $80 billion by the end of the decade. This target, unveiled by CEO Pascal Soriot, reflects AstraZeneca’s confidence in its robust pipeline of new medicines, particularly from its biopharma division.
The Rise of AstraZeneca
A decade ago, AstraZeneca faced skepticism regarding its growth forecasts. Today, it stands as the UK’s most valuable company, gaining recognition as a darling of the European pharmaceutical sector. This transformation has brought heightened expectations. In May, during its first investor day in a decade, AstraZeneca revealed its target of $80 billion in revenues by 2030. The initial reaction from analysts was muted, primarily due to anticipation, as some had already adjusted their revenue estimates upwards. Nevertheless, AstraZeneca’s shares have since reached new highs, trading at a forward price/earnings multiple just above its 10-year average of 18.1 times.
A Promising Pipeline
AstraZeneca’s ambitious revenue target hinges on the success of its clinical trials. The company anticipates over 40 phase 3 trial readouts by the end of 2025, with most results expected next year. Quilter Cheviot healthcare analyst Sheena Berry notes that few European pharma groups can match this rigorous schedule. AstraZeneca estimates that successful medicines from these trials could generate $20 billion in revenue by 2030. Although this estimate is not risk-adjusted, investors will gain a clearer picture within the next 18 months about the feasibility of achieving this uplift from 2023’s $45.8 billion revenues. Importantly, the $80 billion target does not factor in potential revenue from future deals, providing a safety net should trial results fall short.
Biopharma Division: A Key Driver
Half of the 20 new medicines AstraZeneca plans to launch by the end of the decade will come from its biopharma division. While often overshadowed by the company’s high-profile oncology business, the biopharma division has been instrumental to AstraZeneca’s success. Notably, it is responsible for Farxiga, the company’s best-selling drug. Farxiga, a diabetes treatment, generated nearly $6 billion in sales in 2023. As Farxiga begins to lose patent protections from 2026, AstraZeneca aims to mitigate revenue loss by combining it with other medications, such as those preserving kidney function in chronic kidney disease patients.
Challenges Ahead
Despite its promising pipeline, AstraZeneca faces significant challenges. Farxiga is involved in the first round of US drug price negotiations, adding uncertainty to its future revenue. Moreover, drug development inherently involves risks, and AstraZeneca allocates a substantial fifth of its annual revenues to research and development. However, Soriot’s team has assessed its pipeline using average industry success rates and currently exceeds these benchmarks. This success rate offers some reassurance that AstraZeneca’s ambitious revenue target is within reach.
Conclusion
AstraZeneca’s strategy to nearly double its revenues by 2030 is a testament to its growth and resilience. By focusing on its biopharma division and leveraging its robust pipeline, AstraZeneca aims to generate significant revenue from new medicines. While challenges remain, the company’s track record and strategic planning provide confidence in its ability to achieve this ambitious goal. As investors and analysts closely monitor the outcomes of upcoming clinical trials, AstraZeneca’s journey towards $80 billion in revenues will be a defining narrative in the pharmaceutical industry.
Related: Summit Therapeutics & AstraZeneca Shine at Major Cancer conference
Source: Financial Times